Investor Presentaiton

FY 2023 Segment Performance Biopharmaceutical and Diagnostic Solutions Segment (BDS)¹ REVENUE* (€ Million) GROSS PROFIT MARGIN (%) +10% 800 879 FY 2022 FY 2023 34.3 32.9 FY 2022 FY 2023 Revenue increased 11% on a CC basis driven by growth in core Drug Containment Solutions business, despite €93M drop in revenue related to Covid-19 and industry-wide destocking headwinds • HVS revenue grew 25%, representing 34% of total revenue • Revenue from other containment and delivery solutions grew 1% Gross profit margin decreased due to lower EZ-fillⓇ vial volumes, temporary inefficiencies tied to start-up, higher depreciation, FX, and short-term underutilization on some vial lines Engineering Segment¹ +12% REVENUE (€ Million) 184 206 FY 2022 FY 2023 GROSS PROFIT MARGIN (%) SG, Stevanato Group 21.6 FY 2022 21.0 Revenue increased 12% driven by higher sales in visual inspection systems, assembly and packaging machines and after-sales support services. Gross profit margin decrease due to lower marginality on specific projects in process → managing through a large volume of work in progress. Our main priority for 2024 is execution and shortening lead times FY 2023 All comparisons refer to FY 2022 unless otherwise specified. Rounded figures Stevanato Group Investor Presentation, March 2024 22

View entire presentation